Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Agriculture appropriations

This article was originally published in The Gray Sheet

Executive Summary

President Bush signs bill Nov. 30 authorizing $179.5 mil. for CDRH, up 8.7% from FY 2001. The measure also provides a $15 mil. increase for bovine spongiform encephalopathy prevention and enforcement, a $10 mil. increase for adverse event monitoring and reporting, a $10 mil. increase for human subject protection and a $10.3 mil increase for inspections and import monitoring...

You may also be interested in...



CDRH Supplemental Funds Will Support Field Hires, IVD Kit Evaluation

CDRH's policy development team for emergency preparedness, led by Acting Deputy Director for Science Lillian Gill, will begin meeting biweekly to discuss how to administer supplemental emergency funds allocated by Congress in the fiscal 2002 Defense appropriations bill, according to agency officials

US FDA Not Changing Assessment Goals Because of Coronavirus-Mandated Telework

Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.

Abbott Launches Five-Minute POC Rapid COVID-19 Test

Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.

UsernamePublicRestriction

Register

MT015759

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel